Format

Send to

Choose Destination
J Fr Ophtalmol. 2015 Mar;38(3):253-63. doi: 10.1016/j.jfo.2014.10.003. Epub 2015 Feb 13.

[Management of macular edema secondary to retinal vein occlusion].

[Article in French]

Author information

1
Centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
2
CHI de Créteil, 40, avenue de Verdun, 94000 Créteil, France; Université Paris XII, 61, avenue du Général-de-Gaulle, 94010 Créteil, France.
3
Hôpital de la Croix-Rousse, CHU de Lyon, 103, Grande-Rue-de-la-Croix-Rousse, 69004 Lyon, France.
4
Centre d'imagerie et de laser, 11, rue Antoine-Bourdelle, 75015 Paris, France; Hôpital Avicenne, 125, rue de Stalingrad, 93000 Bobigny, France.
5
CHU de Nantes, Hôtel Dieu, 1, place Alexis-Ricordeau, 44000 Nantes, France.
6
Centre ophtalmologique Gallien, 68, rue Palais-Gallien, 33000 Bordeaux, France.
7
Fondation ophtalmologique Rothschild, 25-29, rue Manin, 75019 Paris, France.
8
Centre d'ophtalmologie Blatin, 47, rue Blatin, 63000 Clermont-Ferrand, France.
9
Nouvel hôpital civil, hôpitaux universitaires de Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France; Laboratoire de bactériologie (EA-7290), fédération de médecine translationnelle de Strasbourg, université de Strasbourg, 4, rue Blaise-Pascal, CS 90032, 67081 Strasbourg cedex, France.
10
Hôpital Saint Roch, CHU de Nice Sophia Antipolis, 5, rue Pierre-Devoluy, 06000 Nice, France.
11
Service d'ophtalmologie, hôpital Lariboisière, AP-HP, université Paris 7 - Sorbonne Paris-Cité, 2, rue Ambroise-Paré, 75010 Paris, France. Electronic address: ramin.tadayoni@lrb.aphp.fr.

Abstract

BACKGROUND:

In recent years, intravitreal injections have added to the treatment modalities available for macular edema (ME) secondary to retinal vein occlusion (RVO). This article aims to provide an update regarding the management of ME secondary to RVO.

METHODS:

A work group met in order to analyze the literature available on Embase/PubMed, regarding treatments for venous occlusion that have received market approval and are reimbursed in France. In total, 33 articles were selected. Consensus within the group for recommendations was based on this data from the literature review and clinical experience and was reported in this article.

RESULTS:

The management of ME secondary to branch retinal vein occlusion (BRVO) or central vein occlusion of the retina (CRVO) differs on a number of points. Methods of best practice were discussed separately for BRVO and CRVO, taking into account various ocular and associated parameters.

DISCUSSION:

Ranibizumab and dexamethasone implant are the first-line treatments for visual impairment due to ME secondary to RVO. The choice of either of these drugs may take into account various ocular and extraocular parameters. A change of treatment to one or the other or to laser may also be considered during follow-up.

KEYWORDS:

Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone; Dexaméthasone; Macular edema; Occlusion de branche veineuse rétinienne; Occlusion de veine centrale de la rétine; Occlusion veineuse rétinienne; Ranibizumab; Retinal vein occlusion; Œdème maculaire

PMID:
25683131
DOI:
10.1016/j.jfo.2014.10.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center